Atrial Fibrillation in Philadelphia Chromosome–negative Myeloproliferative Neoplasms: Thromboinflammatory Crosstalk with a Focus on the NLRP3 Inflammasome
Thrombosis and Haemostasis · 23.12.2025
DOI: 10.1055/a-2767-0451 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 23.12.2025. Verfasst von Olga Demska und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 101 Literaturangaben.
Abstract (Originalsprache)
The Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs) and atrial fibrillation (AF) share a common proinflammatory and prothrombotic phenotype. Despite this overlap, patients with coexisting MPNs and AF remain undertreated and poorly characterized, with no specific antithrombotic guidelines addressing this dual pathology. Emerging evidence identifies the nucleotide-binding domain (NOD)-like receptor protein 3 (NLRP3) inflammasome as a central and common mediator of vascular diseases. This review explores the pathophysiologic convergence between MPNs and AF, with a focus on the NLRP3 inflammasome and its downstream cytokines (IL-1β, IL-18), as well as neutrophil extracellular traps (NETs), as unifying drivers of thrombosis, atrial remodeling, and clonal propagation. In MPNs, NLRP3 is activated by JAK2-driven inflammation and sterile danger signals, sustaining a cytokine milieu that promotes pyroptosis, fibrosis, and platelet–leukocyte–endothelial interactions. In AF, inflammasome overactivation in cardiomyocytes and fibroblasts contributes to ectopic activity, electrical remodeling, and fibrosis. NETs, which are enhanced by NLRP3, amplify thrombosis and may link the hematologic and cardiovascular components of the association between MPNs and AF. We critically evaluate the translational potential of inflammasome-derived biomarkers and identify NLRP3 inhibition as a promising adjunctive strategy in MPN patients with AF. The review calls for prospective studies to redefine antithrombotic management in this overlooked population, incorporating molecular, inflammatory, and arrhythmogenic risk dimensions.
Autor:innen und Institutionen
- Department of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland.
- Department of Pharmacology, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland.
- Department of Cardiology, Zealand University Hospital, Roskilde, Denmark.
- Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
- Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Department of Clinical Biochemistry, Zealand University Hospital, Køge, Denmark.
ORCID-Profile: Olga Demska, Marta Szandruk-Bender, Niels Eske Bruun, Vibe Skov, Lasse Kjær, Morten Kranker Larsen, Christina Ellervik, Sebastian Szmit, Hans Carl Hasselbalch, Marta Sobas
Zitieren
APA
Demska, O., Szandruk-Bender, M., Bruun, N. E., Skov, V., Kjær, L., Larsen, M. K., Ellervik, C., Szmit, S., Hasselbalch, H. C., & Sobas, M. (2025). Atrial Fibrillation in Philadelphia Chromosome–negative Myeloproliferative Neoplasms: Thromboinflammatory Crosstalk with a Focus on the NLRP3 Inflammasome. Thrombosis and Haemostasis. https://doi.org/10.1055/a-2767-0451
Vancouver
Demska O, Szandruk-Bender M, Bruun NE, Skov V, Kjær L, Larsen MK, et al. Atrial Fibrillation in Philadelphia Chromosome–negative Myeloproliferative Neoplasms: Thromboinflammatory Crosstalk with a Focus on the NLRP3 Inflammasome. Thrombosis and Haemostasis. 2025. doi:10.1055/a-2767-0451
BibTeX
@article{Demska2025,
author = {Demska, Olga and Szandruk-Bender, Marta and Bruun, Niels Eske and Skov, Vibe and Kjær, Lasse and Larsen, Morten Kranker and Ellervik, Christina and Szmit, Sebastian and Hasselbalch, Hans Carl and Sobas, Marta},
title = {Atrial Fibrillation in Philadelphia Chromosome–negative Myeloproliferative Neoplasms: Thromboinflammatory Crosstalk with a Focus on the NLRP3 Inflammasome},
journal = {Thrombosis and Haemostasis},
year = {2025},
doi = {10.1055/a-2767-0451}
}
EUVIMED